B.Riley FBR Believes Endo International (ENDP) Still Has Room to Grow

In a report released today, David Buck from B.Riley FBR reiterated a Buy rating on Endo International (NASDAQ: ENDP), with a price target of $18.50. The company’s shares opened today at $15.83, close to its 52-week high of $17.34.

According to TipRanks.com, Buck is a 4-star analyst with an average return of 14.4% and a 73.1% success rate. Buck covers the Healthcare sector, focusing on stocks such as Corcept Therapeutics Inc, Spectrum Pharmaceuticals, and Supernus Pharmaceuticals.

Currently, the analyst consensus on Endo International is a Moderate Buy with an average price target of $14.19, a -10.4% downside from current levels. In a report released today, Citigroup also maintained a Buy rating on the stock with a $19 price target.

.

See today’s analyst top recommended stocks >>

The company has a one-year high of $17.34 and a one-year low of $5.27. Currently, Endo International has an average volume of 6.13M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Endo International Plc operates as a pharmaceutical company. It focuses on developing, manufacturing, and distributing of branded and generic pharmaceutical products. The company operates through the following segments: U.S. Branded Pharmaceuticals, U.S. Generic pharmaceuticals and International Pharmaceuticals.